Multiple Myeloma | Specialty

Personalized Medicine Moving to Forefront of Hematologic Malignancies

November 3rd 2017

Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.

Dr. Stadtmauer on Current Challenges With Multiple Myeloma

November 3rd 2017

FDA Grants BCMA Antibody-Drug Conjugate Breakthrough Status for Myeloma

November 2nd 2017

The FDA has granted GSK2857916 a breakthrough therapy designation for patients with relapsed/refractory multiple myeloma.

Dr. Hofmeister Discusses Sequencing Treatment in Myeloma

October 31st 2017

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses sequencing treatment in multiple myeloma.

Expert Sheds Light on Role of Combinations, Transplant in Myeloma

October 27th 2017

Jayesh Mehta, MD, discusses combination therapies in multiple myeloma, as well as the continued importance of stem cell transplant.

Dr. Rosko on Treatment for Elderly Patients With Multiple Myeloma

October 27th 2017

Ashley Rosko, MD, assistant professor in the Division of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment for elderly patients with multiple myeloma.

Dr. Mehta Discusses Combinations in Multiple Myeloma

October 26th 2017

Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

Carfilzomib Effective in Myeloma at Less Frequent, Higher Dose

October 24th 2017

Higher-dose, once-weekly carfilzomib (Kyprolis) demonstrated superior efficacy for patients with relapsed/refractory multiple myeloma compared with a lower-dose, twice-weekly regimen.

Lenalidomide Maintenance Post-ASCT Improves Survival in Myeloma

October 13th 2017

Maintenance therapy with lenalidomide following autologous stem-cell transplantation conferred a survival benefit for patients with newly diagnosed multiple myeloma.

Dr. Kumar on Properly Managing Patients With Multiple Myeloma

October 13th 2017

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses properly managing patients with multiple myeloma.

VCD Induction Induces High Response Rates in Myeloma

October 12th 2017

Induction therapy with bortezomib, cyclophosphamide, and dexamethasone induced strong response rates in treatment-naïve patients with multiple myeloma.

Strategies Explored to Enhance Treatment of Elderly Myeloma Patients

October 12th 2017

Ashley Rosko, MD, discusses available therapies, others under investigation, and supportive care methods being utilized for patients with multiple myeloma.

Dr. Callander Discusses Combinations in Multiple Myeloma

October 11th 2017

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.

Dr. Callander on Treatment Considerations in Multiple Myeloma

October 10th 2017

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.

Treatment for Relapsed/Refractory Multiple Myeloma Based on Biology, Time to Relapse

October 8th 2017

The treatment approach for patients with relapsed/refractory multiple myeloma should be tailored based on biology of the disease, frailty of the patient, and comorbidities.

Managing Newly-Diagnosed Multiple Myeloma

October 8th 2017

Shaji K. Kumar, MD, discusses proper diagnosis, risk stratification, and personalized medicine for patients with newly-diagnosed multiple myeloma.

Dr. Kumar on the Management of Newly Diagnosed Patients With Multiple Myeloma

October 7th 2017

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.

Dr. Hofmeister on the Treatment of Patients with Newly Diagnosed Myeloma

October 3rd 2017

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.

Japan Approves Daratumumab for Relapsed/Refractory Myeloma

October 3rd 2017

The Japanese Ministry of Health, Labor and Welfare has approved the use of daratumumab (Darzalex) for the treatment of adults with relapsed/refractory multiple myeloma.

Experts Discuss Advanced Therapies in Relapsed/Refractory Multiple Myeloma

October 3rd 2017

The advent of new agents and new classes of agents for treating relapsed or refractory multiple myeloma, a notably complex disease state, has stimulated efforts to identify the optimal way to sequence or combine these therapies.